Previous 10 | Next 10 |
- Initial data show encouraging clinical activity with manageable safety profile - No neurotoxicity observed to date in patients treated with AUTO3 + pembrolizumab Data presented at EHA-EBMT 2nd European CAR T Cell Meeting points to potential differentiated profile for ...
LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its previously announced underwritten public offering of American Depositary S...
LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces that the Company’s Founder and Chief Scientific Officer, Martin Pulé, will be giving th...
Gainers: Trans World Entertainment TWMC +260% . More news on: Kaleido BioSciences, Inc., SLM Corporation, Bat Group, Inc., , , Stocks on the move Read more ...
Shares of Autolus Therapeutics (NASDAQ: AUTL) are plunging today, down 18.9% as of 11:16 a.m. EST, after the biopharmaceutical company announced the pricing of a public stock offering following Wednesday's market close. Autolus is selling 7.25 million shares for $11 apiece. Secondary stock ...
Genprex (NASDAQ: GNPX ) -37% on pricing $8M stock offering. More news on: Genprex, Inc., Applied Genetic Technologies Corporation, Tetraphase Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Autolus Therapeutics (NASDAQ: AUTL ) has priced a public offering of 7.25M ADS at $11 each. More news on: Autolus Therapeutics plc, Healthcare stocks news, Read more ...
The following slide deck was published by Autolus Therapeutics plc in conjunction with this Read more ...
LONDON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, is presenting at the 38 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 5:00 p...
Company Overview Autolus Therapeutics ( AUTL ) is a clinical-stage biotechnology company developing next-generation Chimeric Antigen Receptor (“CAR”) T cell therapies for the treatment of both hematological cancers and solid tumors. Using their broad suite of proprietary and ...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights befo...
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...